U.S. markets open in 8 hours 4 minutes
  • S&P Futures

    3,267.50
    -7.50 (-0.23%)
     
  • Dow Futures

    26,992.00
    -63.00 (-0.23%)
     
  • Nasdaq Futures

    10,950.25
    -38.75 (-0.35%)
     
  • Russell 2000 Futures

    1,478.60
    -4.20 (-0.28%)
     
  • Crude Oil

    39.50
    +0.19 (+0.48%)
     
  • Gold

    1,918.20
    +7.60 (+0.40%)
     
  • Silver

    24.70
    +0.32 (+1.30%)
     
  • EUR/USD

    1.1763
    -0.0010 (-0.08%)
     
  • 10-Yr Bond

    0.6710
    0.0000 (0.00%)
     
  • Vix

    27.78
    +1.95 (+7.55%)
     
  • GBP/USD

    1.2807
    -0.0011 (-0.08%)
     
  • USD/JPY

    104.5250
    -0.1550 (-0.15%)
     
  • BTC-USD

    10,464.92
    +27.20 (+0.26%)
     
  • CMC Crypto 200

    213.52
    -22.07 (-9.37%)
     
  • FTSE 100

    5,804.29
    -202.76 (-3.38%)
     
  • Nikkei 225

    23,360.30
    +40.90 (+0.18%)
     

Sarepta Rises 5.3%, Helping XBI’s Small-Cap Stocks

Peter Neil

XBI Rises amid a Flat Market

(Continued from Prior Part)

XBI small-caps muted by large and mid-cap stocks

The small-cap (small capitalization) stocks of the SPDR S&P Biotech ETF (XBI) gained 0.5% on November 17, 2015. XBI’s small-cap stocks underperformed its large-caps, its mid-caps, and XBI itself. However, the small-cap stocks outperformed the SPDR S&P 500 ETF (SPY), which gave a return of -0.05%.

As of November 17, 2015, XBI has 60 small-cap stocks in its portfolio with a market capitalization ranging from $300 million to $2 billion. Small-cap stocks account for ~57.8% of XBI’s portfolio. Out of 60 stocks, 22 ended up in the red and 38 gave positive returns.

XBI’s small-cap stocks include Amicus Therapeutics (FOLD), AMAG Pharmaceuticals (AMAG), and Merrimack Pharmaceuticals (MACK), which gave returns of -6.8%, 4.5%, and 4.7%, respectively.

The above graph reflects the collective performance of XBI’s small-cap stocks in comparison with XBI and SPY. Since the beginning of November 2015, XBI’s small-cap stocks have given a return of 3%, while XBI returned 3.3% and SPY returned -1.2%. The small-caps underperformed XBI but outperformed SPY.

Sarepta announces positive data for eteplirsen, gains 5.3%

Sarepta Therapeutics (SRPT) gained 5.3% on positive data for the drug eteplirsen.

As per its press release, SRPT announced, “The Annals of Neurology published online positive efficacy and safety results from a Phase IIb long-term open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (or DMD) amenable to exon 51 skipping. The study found that at three years of treatment, patients experienced a slower rate of disease progression when compared to untreated matched historical controls and the investigational drug continued to be well-tolerated.”

SRPT closed at $27.3 and was trading below its 50- and 100-day moving averages. SRPT witnessed high trading volumes, with ~1.8 million shares being traded as compared to its five-day average trading volume of ~884,000 shares per day.

SRPT has a book value of $2.94. With its current price, the stock is trading at a price-to-book value (or PBV) of 9.30x. SRPT has a weight of 1.4% in XBI’s portfolio.

Continue to Next Part

Browse this series on Market Realist: